Drug intelligence / Profile preview

NBP607B

Development stage: Unknown
Lead developer: SK bioscience
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

NBP607B is an adjuvanted, cell-based influenza vaccine candidate developed by SK bioscience. It is a high-immunogenicity formulation designed to enhance protective efficacy, particularly in the elderly population, by incorporating a proprietary adjuvant developed by the Vaccine Formulation Institute (VFI). The vaccine is based on SK bioscience's existing cell-culture technology used in SKYCellflu, which is an inactivated quadrivalent influenza vaccine. NBP607B aims to address the reduced immune response typically observed in older adults with standard influenza vaccines. It is currently being evaluated in Phase 1/2 clinical trials to assess its safety and immunogenicity compared to standard vaccines.

Other names: adjuvanted SKYCellflu

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on NBP607B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBP607B.

Explore the full profile